Allianz Asset Management GmbH acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 754,759 shares of the biopharmaceutical company’s stock, valued at approximately $11,381,000. Allianz Asset Management GmbH owned 0.45% of Amicus Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Janus Henderson Group PLC purchased a new position in shares of Amicus Therapeutics during the second quarter worth approximately $70,762,000. Farallon Capital Management LLC purchased a new position in shares of Amicus Therapeutics during the second quarter worth approximately $30,210,000. Eagle Asset Management Inc. purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $40,450,000. Jennison Associates LLC increased its position in shares of Amicus Therapeutics by 9.4% during the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock worth $147,362,000 after acquiring an additional 838,267 shares during the period. Finally, FMR LLC increased its position in shares of Amicus Therapeutics by 3.4% during the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after acquiring an additional 705,153 shares during the period.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $12.85 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter in the prior year, the business posted ($0.33) earnings per share. Amicus Therapeutics’s revenue for the quarter was up 419.0% on a year-over-year basis. equities analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.

In other news, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO William D. Baird III sold 40,000 shares of the stock in a transaction that occurred on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $570,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 692,643 shares of company stock worth $9,899,547. Insiders own 3.40% of the company’s stock.

A number of equities analysts have recently commented on the stock. Leerink Swann reaffirmed a “buy” rating and set a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $16.00 target price on shares of Amicus Therapeutics in a research report on Monday, September 25th. Zacks Investment Research lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Bank of America raised their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $17.81.

COPYRIGHT VIOLATION WARNING: “Allianz Asset Management GmbH Invests $11.38 Million in Amicus Therapeutics, Inc. (FOLD) Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/allianz-asset-management-gmbh-invests-11-38-million-in-amicus-therapeutics-inc-fold-stock/1767105.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.